Cover Image
Market Research Report
Product code 
997338

Market Spotlight: Acute Decompensated Heart Failure (ADHF)

Published: | Datamonitor Healthcare | 28 Pages | Delivery time: 1-2 business days

Price

Back to Top
Market Spotlight: Acute Decompensated Heart Failure (ADHF)
Published: March 3, 2021
Datamonitor Healthcare
Content info: 28 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

This Market Spotlight report covers the Acute Decompensated Heart Failure (ADHF) market, comprising key marketed and pipeline drugs, upcoming events, clinical trials, probability of success, and epidemiology information.

Key Takeaways:

Approved drugs in the acute decompensated heart failure (ADHF) space target natriuretic peptide receptors, phosphodiesterase 3, potassium channels, and troponin-C. All of the approved therapies are administered via the intravenous route, with two drugs also being available in an oral formulation.

The greatest proportion of industry-sponsored drugs in active clinical development for ADHF are in Phase I. Therapies in development for ADHF focus on targets such as Na-K-Cl cotransporter, guanylate cyclase, ryanodine receptor, sarcoplasmic reticulum Ca2+-ATPase, troponin, beta-3 adrenergic receptor, vasopressin receptors, and relaxin family peptide receptors 1-4. These therapies are administered via the oral, intravenous, and subcutaneous routes.

High-impact upcoming events for drugs in the ADHF space comprise topline Phase II trial results for istaroxime, topline Phase IIa trial results for APD418, and topline Phase IIb trial results for cimlanod.

The overall likelihood of approval of a Phase I ADHF asset is 1.6%, and the average probability a drug advances from Phase III is 28.6%. Drugs, on average, take 12.9 years from Phase I to approval, compared to 10.1 years in the overall cardiovascular space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for ADHF have been in the late phases of development, with 58% of trials in Phase III-IV, and 42% in Phase I-II.

Clinical trial activity in the ADHF space is dominated by completed trials. Johnson & Johnson has the highest number of completed clinical trials for ADHF, with 17 trials.

Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for ADHF, followed by Novartis.

Table of Contents
Product Code: DMKC0203494

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition
  • Symptoms
  • Patient subtypes
  • Risk factors
  • Diagnosis

TREATMENT

  • Diuretics
  • Vasodilator therapy
  • Ultrafiltration (UF)
  • Inotropes
  • Natriuretic peptides
  • Vasopressors/Beta blockers/ACE inhibitors
  • Circulatory assist devices
  • Other therapies

EPIDEMIOLOGY

  • ADHF incidence

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for ADHF in the US
  • Figure 2: Pipeline drugs for ADHF, by company
  • Figure 3: Pipeline drugs for ADHF, by drug type
  • Figure 4: Pipeline drugs for ADHF, by classification
  • Figure 5: Key upcoming events in ADHF
  • Figure 6: Probability of success in the ADHF pipeline
  • Figure 7: Clinical trials in ADHF
  • Figure 8: Top 10 drugs for clinical trials in ADHF
  • Figure 9: Top 10 companies for clinical trials in ADHF
  • Figure 10: ADHF trials status
  • Figure 11: ADHF trials sponsors, by phase

LIST OF TABLES

  • Table 1: Marketed drugs for ADHF
  • Table 2: Pipeline drugs for ADHF in the US